Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2943983 | Journal of the American College of Cardiology | 2014 | 16 Pages |
Abstract
Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This “omic” approach recently resulted in new targets for reducing CVD events.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Robert S. Rosenson, Michael H. Davidson, Benjamin J. Hirsh, Sekar Kathiresan, Daniel Gaudet,